Is KLRA or KNSA more undervalued in 2026?

CirclFi compares Kailera Therapeutics, Inc. (KLRA) and Kiniksa Pharmaceuticals Interna (KNSA) using 13 institutional-grade valuation models. KLRA has a Quality of Company score of 1.7/10 while KNSA scores 5.5/10.

Which is a better buy — KLRA or KNSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KLRA and KNSA valuations compare?

KLRA at $22.94 and KNSA at $48.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KLRA vs KNSA Valuation Comparison 2026 — Intrinsic Value Analysis

KLRA

Pharmaceutical Preparations

Kailera Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$22.94

Last close

Models

5/13

Active

KNSA

Pharmaceutical Preparations

Kiniksa Pharmaceuticals Interna

Quality

5.5

out of 10

Value Trap

SAFE

Price

$48.38

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KLRA Fair Value	KLRA Upside	KNSA Fair Value	KNSA Upside
Bayesian DCF	Intrinsic	$5.97	-74.0%	$6.16	-87.3%
Earnings Power Value	Intrinsic	—	—	$9.70	-79.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.09	-86.5%	$17.36	-64.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KLRA vs KNSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KLRA vs KNSA — Which Stock Is More Undervalued?

KNSA scores higher with a 5.5/10 quality rating vs KLRA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kailera Therapeutics, Inc. (KLRA) and Kiniksa Pharmaceuticals Interna (KNSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KLRA currently trades at $22.94 with a QOC of 1.7/10, while KNSA trades at $48.38 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).